The following links may provide you with more information about your sight, questions about glaucoma, and other resources.
These Web sites are neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services on these sites.
The Glaucoma Foundation's mission is to stimulate and support basic and applied research in glaucoma, to gain and disseminate new information about the biological causes and treatment of glaucoma, and to identify and develop novel approaches to preserve visual function and reverse blindness caused by glaucoma.
The Glaucoma Research Foundation works to prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.
Materials from the National Eye Institute can help people learn more about glaucoma. This site also has an interactive quiz to test one's knowledge.
Lighthouse International is a leading nonprofit organization committed to preserving vision and providing rehabilitation services to help people of all ages with the challenges of vision loss.
Prevent Blindness America is the nation's leading volunteer organization for eye health and safety. They're committed to fighting blindness and saving sight.
The mission of the Foundation Fighting Blindness is to drive the research that can provide treatments, preventions, and cures for people affected by the entire spectrum of retinal degenerative diseases.
All Eyes on Glaucoma™ is a program created to raise public awareness of glaucoma. Information on risk factors, stories, support, and news are available on the site.
XALATAN is for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.
Like all medicines, XALATAN can have side effects. These side effects are usually mild and tolerable and may include blurred vision, burning and stinging, eye redness, the feeling of something in the eye, eye itching, increased pigmentation (darkening) of eye color, or irritation of the clear front surface of the eye.
XALATAN may slowly cause darkening of the eye color due to increased brown color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes can increase as long as XALATAN is administered and eye color changes are likely to be permanent.
The recommended dosage is one drop (1.5 µg) in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal.
There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products.
This Web site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries.
The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.
Pfizer is a licensee of the TRUSTe Privacy Program© 2008 Pfizer Inc. All rights reserved.
XLU00206B